A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer

ConclusionsEribulin is active in HER2 − breast cancer. This study reveals that provider-assessed AEs can vary greatly from patient experiences. Future studies should incorporate CTCAE and PRO instruments to improve reporting of treatment-related AEs.ClinicalTrials.gov Registration: NCT01827787
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research